Aspergillus-specific immune reconstitution and outcome of invasive aspergillosis in 10 patients who received Aspergillus-specific T-cell therapy
Patient no. . | Invasive aspergillosis before cell therapy . | Galactomannan antigenemia before T-cell therapy,*ng/mL . | Cell therapy, day after transplantation . | Aspergillus-specific CD4+ reconstitution, day after cell therapy . | Galactomannan antigenemia after cell therapy,†ng/mL . | Outcome (time after diagnosis, wk) . |
|---|---|---|---|---|---|---|
| 1 | P: mult/bilat + pl eff + CNS | 3.4 ± 0.6 | 37 | 21 | 0.8 ± 0.1 | Death (4) |
| 2 | P: mult/bilat + sin | 4.2 ± 0.4 | 23 | 21 | 0.3 ± 0.1 | Resolution (4) |
| 3 | P: mult/bilat + pl eff | 1.6 ± 0.5 | 32 | 21 | 0.4 ± 0.1 | Resolution (5) |
| 4 | P: mult/bilat + pl eff | 2.0 ± 0.6 | 32 | 21 | 0.2 ± 0.0 | Resolution (12) |
| 5 | P: monolat + sin | 1.9 ± 0.7 | 25 | 21 | 0.4 ± 0.1 | Resolution (14) |
| 6 | P: mult/bilat | 2.8 ± 0.3 | 17 | 21 | 0.6 ± 0.5 | Resolution (5) |
| 7 | P: mult bilat + pl eff + sin | 2.1 ± 0.5 | 17 | 21 | 0.8 ± 0.1 | Resolution (10) |
| 8 | P: mult/bilat | 2.2 ± 0.1 | 21 | 21 | 0.7 ± 0.2 | Resolution (6) |
| 9 | P: monolat | 3.1 ± 0.2 | 21 | 21 | 0.6 ± 0.2 | Resolution (7) |
| 10 | P: mult/bilat | 3.1 ± 0.3 | 21 | 21 | 0.4 ± 0.3 | Resolution (8) |
Patient no. . | Invasive aspergillosis before cell therapy . | Galactomannan antigenemia before T-cell therapy,*ng/mL . | Cell therapy, day after transplantation . | Aspergillus-specific CD4+ reconstitution, day after cell therapy . | Galactomannan antigenemia after cell therapy,†ng/mL . | Outcome (time after diagnosis, wk) . |
|---|---|---|---|---|---|---|
| 1 | P: mult/bilat + pl eff + CNS | 3.4 ± 0.6 | 37 | 21 | 0.8 ± 0.1 | Death (4) |
| 2 | P: mult/bilat + sin | 4.2 ± 0.4 | 23 | 21 | 0.3 ± 0.1 | Resolution (4) |
| 3 | P: mult/bilat + pl eff | 1.6 ± 0.5 | 32 | 21 | 0.4 ± 0.1 | Resolution (5) |
| 4 | P: mult/bilat + pl eff | 2.0 ± 0.6 | 32 | 21 | 0.2 ± 0.0 | Resolution (12) |
| 5 | P: monolat + sin | 1.9 ± 0.7 | 25 | 21 | 0.4 ± 0.1 | Resolution (14) |
| 6 | P: mult/bilat | 2.8 ± 0.3 | 17 | 21 | 0.6 ± 0.5 | Resolution (5) |
| 7 | P: mult bilat + pl eff + sin | 2.1 ± 0.5 | 17 | 21 | 0.8 ± 0.1 | Resolution (10) |
| 8 | P: mult/bilat | 2.2 ± 0.1 | 21 | 21 | 0.7 ± 0.2 | Resolution (6) |
| 9 | P: monolat | 3.1 ± 0.2 | 21 | 21 | 0.6 ± 0.2 | Resolution (7) |
| 10 | P: mult/bilat | 3.1 ± 0.3 | 21 | 21 | 0.4 ± 0.3 | Resolution (8) |
P indicates pneumonia; mult/bilat, multiple, bilateral lung lesions; pl eff, pleural effusion; CNS, brain lesion; sin, maxillary and etmoidal sinusitis; and monolat, monolateral lung lesions.
Mean ± SD of at least 3 assessments of serum Aspergillus galactomannan antigen levels by sandwich immunocapture ELISA. Values more than 1 ng/mL were considered indicative of invasive aspergillosis
Mean ± SD of weekly assessments from 6 to 12 weeks after T-cell therapy. All patients also received liposomal amphotericin therapy